Last reviewed · How we verify
CB-011
At a glance
| Generic name | CB-011 |
|---|---|
| Also known as | Cyclophosphamide, Fludarabine |
| Sponsor | Caribou Biosciences, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Long-Term Follow-up Study
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-011 CI brief — competitive landscape report
- CB-011 updates RSS · CI watch RSS
- Caribou Biosciences, Inc. portfolio CI